Executive Panel: Recent Advances and Future Perspectives for AI in the Drug Discovery and Development Value Chain | Kisaco Research
Sponsor(s): 
MilliporeSigma
Speaker(s): 
Moderator

Author:

David Champagne

Senior Partner
McKinsey & Company

David Champagne is a Senior Partner at McKinsey and leads McKinsey’s global Scientific AI practice to help clients in the life sciences industry and beyond drive the next frontier of R&D productivity with AI. The practice covers a broad range of AI capabilities across Biology, Chemistry, Materials and Physics. David brings together teams of scientific experts from McKinsey’s industry practices with deep technology expertise from QuantumBlack, to develop strategies, blueprints and roadmaps for the technology-driven transformation of product discovery and development processes in industries where science is at the core of innovation.

David Champagne

Senior Partner
McKinsey & Company

David Champagne is a Senior Partner at McKinsey and leads McKinsey’s global Scientific AI practice to help clients in the life sciences industry and beyond drive the next frontier of R&D productivity with AI. The practice covers a broad range of AI capabilities across Biology, Chemistry, Materials and Physics. David brings together teams of scientific experts from McKinsey’s industry practices with deep technology expertise from QuantumBlack, to develop strategies, blueprints and roadmaps for the technology-driven transformation of product discovery and development processes in industries where science is at the core of innovation.

Author:

Melissa Landon

Head, Commercial & Business Development, AI & Automation
MilliporeSigma

Dr. Melissa (“Mel”) Landon leads Commercial and Business Development for AI and Automation at Millipore Sigma, the Life Science business of Merck KGaA. With 20 years of experience of building cutting edge platforms across pharma and tech, Mel’s current work focuses on scaling intelligent automation and AI solutions that bridge scientific innovation with commercial value. She brings to this role a cross-disciplinary background spanning life sciences, technology partnerships, and enterprise transformation. Prior to joining MilliporeSigma, Melissa served as Chief Strategy Officer at Cyclica, an AI-enabled tech bio company (acquired by Recursion in 2023). Melissa completed her PhD in Bioinformatics at Boston University and performed postdoctoral studies in biochemistry and X-ray crystallography at Brandeis University. 

Melissa Landon

Head, Commercial & Business Development, AI & Automation
MilliporeSigma

Dr. Melissa (“Mel”) Landon leads Commercial and Business Development for AI and Automation at Millipore Sigma, the Life Science business of Merck KGaA. With 20 years of experience of building cutting edge platforms across pharma and tech, Mel’s current work focuses on scaling intelligent automation and AI solutions that bridge scientific innovation with commercial value. She brings to this role a cross-disciplinary background spanning life sciences, technology partnerships, and enterprise transformation. Prior to joining MilliporeSigma, Melissa served as Chief Strategy Officer at Cyclica, an AI-enabled tech bio company (acquired by Recursion in 2023). Melissa completed her PhD in Bioinformatics at Boston University and performed postdoctoral studies in biochemistry and X-ray crystallography at Brandeis University. 

Author:

David Hallett

Chief Scientific Officer
Recursion

David Hallett

Chief Scientific Officer
Recursion

Author:

Morten Sogaard

Senior Vice President & Head, Astellas Innovation Lab
Astellas Pharma

Morten Sogaard

Senior Vice President & Head, Astellas Innovation Lab
Astellas Pharma

Author:

Peter Clark

Vice President, Digital Chemistry & Design
Novo Nordisk RDUS

Peter Clark

Vice President, Digital Chemistry & Design
Novo Nordisk RDUS
Time: 
9:00 AM - 9:45 AM
Session Type: 
Panel